Applied DNA Sciences Partners with Alphazyme to Scale-Up Manufacturing of Linea™ RNAP

Applied DNA Sciences, Inc., a leader in PCR-based DNA technologies, has announced a partnership with Alphazyme LLC, a global specialty enzyme provider. This collaboration aims to scale the manufacturing of Applied DNA's proprietary Linea™ RNA polymerase (RNAP) to meet the increasing demand for the company's Linea™ IVT platform. The enhanced manufacturing capability is anticipated to align with Applied DNA's initiation of GMP manufacturing for Linea™ DNA IVT templates.

The agreement between the two companies involves Alphazyme performing manufacturing process development to scale Linea RNAP from research to commercial scale. This scale-up is critical for facilitating the growing demand for Applied DNA's Linea™ IVT platform, which aims to improve mRNA manufacturing by enabling higher yields, reducing contamination, and simplifying production workflows.

Dr. James A. Hayward, president and CEO of Applied DNA, highlighted the importance of this partnership in advancing their GMP manufacturing capabilities and responding to the growing interest in their Linea IVT platform. He emphasized the critical nature of manufacturing Linea RNAP at a commercial scale for the success of their approach. Chad Decker, Vice President and General Manager of Alphazyme, echoed the sentiment, underlining the joint commitment to advancing the manufacture of high-quality enzymes essential for mRNA manufacturing.

The collaboration between Applied DNA Sciences and Alphazyme represents a significant step towards enhancing the manufacturing capacity and cost-effectiveness of key components used in producing therapeutics and vaccines, potentially impacting the broader life sciences sector.